198 related articles for article (PubMed ID: 35396982)
1. Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions.
Lavelle TA; Feng X; Keisler M; Cohen JT; Neumann PJ; Prichard D; Schroeder BE; Salyakina D; Espinal PS; Weidner SB; Maron JL
Genet Med; 2022 Jun; 24(6):1349-1361. PubMed ID: 35396982
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness frameworks for comparing genome and exome sequencing versus conventional diagnostic pathways: A scoping review and recommended methods.
Ferket BS; Baldwin Z; Murali P; Pai A; Mittendorf KF; Russell HV; Chen F; Lynch FL; Lich KH; Hindorff LA; Savich R; Slavotinek A; Smith HS; Gelb BD; Veenstra DL
Genet Med; 2022 Oct; 24(10):2014-2027. PubMed ID: 35833928
[TBL] [Abstract][Full Text] [Related]
3. Real-world diagnostic outcomes and cost-effectiveness of genome-wide sequencing for developmental and seizure disorders: Evidence from Canada.
Regier DA; Loewen R; Chan B; Ehman M; Pollard S; Friedman JM; Stockler-Ipsiroglu S; van Karnebeek C; Race S; Elliott AM; Dragojlovic N; Lynd LD; Weymann D
Genet Med; 2024 Apr; 26(4):101069. PubMed ID: 38205742
[TBL] [Abstract][Full Text] [Related]
4. Long-term economic impacts of exome sequencing for suspected monogenic disorders: diagnosis, management, and reproductive outcomes.
Schofield D; Rynehart L; Shresthra R; White SM; Stark Z
Genet Med; 2019 Nov; 21(11):2586-2593. PubMed ID: 31110331
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of genome sequencing for diagnosing patients with undiagnosed rare genetic diseases.
Incerti D; Xu XM; Chou JW; Gonzaludo N; Belmont JW; Schroeder BE
Genet Med; 2022 Jan; 24(1):109-118. PubMed ID: 34906478
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Genome and Exome Sequencing in Children Diagnosed with Autism Spectrum Disorder.
Yuen T; Carter MT; Szatmari P; Ungar WJ
Appl Health Econ Health Policy; 2018 Aug; 16(4):481-493. PubMed ID: 29651777
[TBL] [Abstract][Full Text] [Related]
8. Narrowing the diagnostic gap: Genomes, episignatures, long-read sequencing, and health economic analyses in an exome-negative intellectual disability cohort.
Dias KR; Shrestha R; Schofield D; Evans CA; O'Heir E; Zhu Y; Zhang F; Standen K; Weisburd B; Stenton SL; Sanchis-Juan A; Brand H; Talkowski ME; Ma A; Ghedia S; Wilson M; Sandaradura SA; Smith J; Kamien B; Turner A; Bakshi M; Adès LC; Mowat D; Regan M; McGillivray G; Savarirayan R; White SM; Tan TY; Stark Z; Brown NJ; Pérez-Jurado LA; Krzesinski E; Hunter MF; Akesson L; Fennell AP; Yeung A; Boughtwood T; Ewans LJ; Kerkhof J; Lucas C; Carey L; French H; Rapadas M; Stevanovski I; Deveson IW; Cliffe C; Elakis G; Kirk EP; Dudding-Byth T; Fletcher J; Walsh R; Corbett MA; Kroes T; Gecz J; Meldrum C; Cliffe S; Wall M; Lunke S; North K; Amor DJ; Field M; Sadikovic B; Buckley MF; O'Donnell-Luria A; Roscioli T
Genet Med; 2024 May; 26(5):101076. PubMed ID: 38258669
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive iterative approach is highly effective in diagnosing individuals who are exome negative.
Shashi V; Schoch K; Spillmann R; Cope H; Tan QK; Walley N; Pena L; McConkie-Rosell A; Jiang YH; Stong N; Need AC; Goldstein DB;
Genet Med; 2019 Jan; 21(1):161-172. PubMed ID: 29907797
[TBL] [Abstract][Full Text] [Related]
10. Exome and genome sequencing in a heterogeneous population of patients with rare disease: Identifying predictors of a diagnosis.
Pucel J; Briere LC; Reuter C; Gochyyev P; ; LeBlanc K
Genet Med; 2024 Jun; 26(6):101115. PubMed ID: 38436216
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of the diagnostic and clinical utility of exome and genome sequencing in pediatric and adult patients with rare diseases across diverse populations.
Chung CCY; Hue SPY; Ng NYT; Doong PHL; ; Chu ATW; Chung BHY
Genet Med; 2023 Sep; 25(9):100896. PubMed ID: 37191093
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Whole-Genome vs Whole-Exome Sequencing Among Children With Suspected Genetic Disorders.
Nurchis MC; Radio FC; Salmasi L; Heidar Alizadeh A; Raspolini GM; Altamura G; Tartaglia M; Dallapiccola B; Pizzo E; Gianino MM; Damiani G
JAMA Netw Open; 2024 Jan; 7(1):e2353514. PubMed ID: 38277144
[TBL] [Abstract][Full Text] [Related]
13. The performance of genome sequencing as a first-tier test for neurodevelopmental disorders.
van der Sanden BPGH; Schobers G; Corominas Galbany J; Koolen DA; Sinnema M; van Reeuwijk J; Stumpel CTRM; Kleefstra T; de Vries BBA; Ruiterkamp-Versteeg M; Leijsten N; Kwint M; Derks R; Swinkels H; den Ouden A; Pfundt R; Rinne T; de Leeuw N; Stegmann AP; Stevens SJ; van den Wijngaard A; Brunner HG; Yntema HG; Gilissen C; Nelen MR; Vissers LELM
Eur J Hum Genet; 2023 Jan; 31(1):81-88. PubMed ID: 36114283
[TBL] [Abstract][Full Text] [Related]
14. Exome Sequencing for Prenatal Detection of Genetic Abnormalities in Fetal Ultrasound Anomalies: An Economic Evaluation.
Kodabuckus SS; Quinlan-Jones E; McMullan DJ; Maher ER; Hurles ME; Barton PM; Kilby MD
Fetal Diagn Ther; 2020; 47(7):554-564. PubMed ID: 31962312
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of genome-wide sequencing for unexplained developmental disabilities and multiple congenital anomalies.
Li C; Vandersluis S; Holubowich C; Ungar WJ; Goh ES; Boycott KM; Sikich N; Dhalla I; Ng V
Genet Med; 2021 Mar; 23(3):451-460. PubMed ID: 33110268
[TBL] [Abstract][Full Text] [Related]
16. Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness.
Stark Z; Schofield D; Martyn M; Rynehart L; Shrestha R; Alam K; Lunke S; Tan TY; Gaff CL; White SM
Genet Med; 2019 Jan; 21(1):173-180. PubMed ID: 29765138
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
[TBL] [Abstract][Full Text] [Related]
18. Case for genome sequencing in infants and children with rare, undiagnosed or genetic diseases.
Bick D; Jones M; Taylor SL; Taft RJ; Belmont J
J Med Genet; 2019 Dec; 56(12):783-791. PubMed ID: 31023718
[TBL] [Abstract][Full Text] [Related]
19. Genomic testing for suspected monogenic kidney disease in children and adults: A health economic evaluation.
Wu Y; Jayasinghe K; Stark Z; Quinlan C; Patel C; McCarthy H; Mallawaarachchi AC; Kerr PG; Alexander S; Mallett AJ; Goranitis I;
Genet Med; 2023 Nov; 25(11):100942. PubMed ID: 37489581
[TBL] [Abstract][Full Text] [Related]
20. Limitations of exome sequencing in detecting rare and undiagnosed diseases.
Burdick KJ; Cogan JD; Rives LC; Robertson AK; Koziura ME; Brokamp E; Duncan L; Hannig V; Pfotenhauer J; Vanzo R; Paul MS; Bican A; Morgan T; Duis J; Newman JH; Hamid R; Phillips JA;
Am J Med Genet A; 2020 Jun; 182(6):1400-1406. PubMed ID: 32190976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
